Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus

Expert Opinion on Biological Therapy

Volumn 9, Issue 2, 2009, Pages 201-206

  Iikuni, Noriko ^a   Hahn, Bevra H ^a   La Cava, Antonio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti DNA antibodies; Immunotherapy; Peptide; Systemic lupus erythematosus

Indexed keywords

DNA ANTIBODY; EDRATIDE; EPITOPE; GAMMA INTERFERON; HUMAN MONOCLONAL ANTIBODY CDR1; IMMUNOGLOBULIN ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 1BETA; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN; PEPTIDE;

ANTIGEN DETECTION; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NEPHRITIS; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THYMUS; CHEMISTRY; IMMUNOLOGY;

MURINAE;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDES;

EID: 65649133407     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802681636     Document Type: Review

References (57)

1. Garza K, Chan V, Ohashi P. T cell tolerance and autoimmunity. Rev Immunogenet 2000;2:2-17 (Pubitemid 30142479)
2. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164
3. + regulatory T cells control autoimmunity? Curr Opin Immunol 2005;17:638-642
4. La Cava A. T regulatory cells in systemic lupus erythematosus. Lupus 2008;17:421-425 (Pubitemid 351798720)
5. Miyara M, Amoura Z, Parizot C, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005;175:8392-8400 (Pubitemid 41798406)
6. Alvarado-Sánchez B, Hernández-Castro B, Portales-Pérez D, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006;27:110-118 (Pubitemid 44528260)
7. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007;178:2579-2588
8. Parietti V, Chifflot H, Muller S, Monneaux F. Regulatory T cells and systemic lupus erythematosus. Ann NY Acad Sci 2007;1108:64-75 (Pubitemid 47528718)
9. Anderton S. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology 2001;104:367-376 (Pubitemid 34037828)
10. Larché M, Wraith D. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005;11: S69-76 (Pubitemid 40562306)
11. Pfeiffer C, Stein J, Southwood S, et al. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995;181:1569-1574
12. Khalil M, Inaba K, Steinman R, et al. T cell studies in a peptide-induced model of systemic lupus erythematosus. J Immunol 2001;166:1667-1674 (Pubitemid 32114648)
13. La Cava A, Hahn BH. Immunotherapy with Ig-derived peptides in SLE: Current status and directions. In: Seward TI, editor, Progress in Systemic Lupus Erythematosus Research. Nova Science Publishers; 2008. p. 131-153
14. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-1175 (Pubitemid 30792198)
15. Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000;6:1176-1182 (Pubitemid 30792199)
16. Weiner H, Mackin G, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259:1321-1324 (Pubitemid 23100270)
17. Raz I, Elias D, Avron A, et al. B-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358:1749-1753 (Pubitemid 33152998)
18. Prakken B, Samodal R, Le T, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 2004;101:4228-4233 (Pubitemid 38405911)
19. Singh R. The potential use of peptides and vaccination to treat systemic lupus erythematosus. Curr Opin Rheumatol 2000;12:399-406 (Pubitemid 30676857)
20. Freed J, Marrs A, VanderWall J, et al. MHC class II-bound self peptides from autoimmune MRL/lpr mice reveal potential T cell epitopes for autoantibody production in murine systemic lupus erythematosus. J Immunol 2000;164:4697-4705 (Pubitemid 30238070)
21. Suh C, Freed J, Cohen P. T cell reactivity to MHC class II-bound self peptides in systemic lupus erythematosus-prone MRL/lpr mice. J Immunol 2003;170:2229-2235 (Pubitemid 36197448)
22. Kaliyaperumal A, Michaels M, Datta S. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 1999;162:5775-5783 (Pubitemid 29314928)
23. Kaliyaperumal A, Michaels M, Datta S. Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. J Immunol 2002;168:2530-2537 (Pubitemid 34171860)
24. Kaliyaperumal A, Mohan C, Wu W, Datta S. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 1996;183:2459-2469 (Pubitemid 26192355)
25. Lu L, Kaliyaperumal A, Boumpas D, Datta S. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 1999;104:345-355
26. Kang H, Michaels M, Berner B, Datta S. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005;174:3247-3255 (Pubitemid 40354027)
27. Suen J, Chuang Y, Tsai B, et al. Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum 2004;50:3250-3259 (Pubitemid 39372002)
28. Wu H, Ward F, Staines N. Histone peptide-induced nasal tolerance: suppression of murine lupus. J Immunol 2002;169:1126-1134 (Pubitemid 34753473)
29. + T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 2004;13:192-200
30. 183-119 peptide. Arthritis Rheum 2001;44:2435-2445
31. 183-119 C terminal peptide in patients with systemic lupus erythematosus. Ann Rheum Dis 2002;61:779-785
32. Talken B, Schäfermeyer K, Bailey C, et al. T cell epitope mapping of the Smith antigen reveals that highly conserved Smith antigen motifs are the dominant target of T cell immunity in systemic lupus erythematosus. J Immunol 2001;167:562-568 (Pubitemid 32567824)
33. + T cells recognize a T cell epitope located within the RNP80 motif of the 70K protein. Eur J Immunol 2000;30:2191-2200
34. 1 lupus mice. Int Immunol 2001;13:1155-1163
35. + T cells from lupus patients by a promiscuous, protective peptide analog. J Immunol 2005;175:5839-5847
36. Monneaux F, Lozano J, Patarroyo M, et al. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur J Immunol 2003;33:287-296 (Pubitemid 36267592)
37. Hahn B, Singh R, Wong W, et al. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 2001;44:432-441 (Pubitemid 32207037)
38. 1 mice via active suppression. Int Immunol 2003;15:205-214
39. Singh R, Ebling F, Sercarz E, Hahn B. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995;96:2990-2996
40. Singh R, Hahn B, Tsao B, Ebling F. Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus. J Clin Invest 1998;102:1841-1849 (Pubitemid 28533831)
41. + T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 2007;178:7649-7657
42. 1 mice suppress in vitro production of antibodies to DNA. J Immunol 2004;173:3542-3548
43. + T cell suppressors. J Immunol 2005;175:7728-7737
44. 1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol 2008;180:2069-2080
45. Hahn B, Anderson M, Le E, La Cava A. Anti-DNA Ig peptides promote regulatory T cell activity in systemic lupus erythematosus patients. Arthritis Rheum 2008;58:2488-2497
46. Sthoeger Z, Dayan M, Tcherniack A, et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 2003;131:385-392 (Pubitemid 36205154)
47. Waisman A, Shoenfeld Y, Blank M, et al. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol 1995;7:689-696
48. Isenberg D, Shoenfeld Y, Madaio M, et al. Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet 1984;2:417-422 (Pubitemid 14059388)
49. Dayan M, Segal R, Sthoeger Z, et al. Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. J Clin Immunol 2000;20:187-194 (Pubitemid 30485879)
50. Mendlovic S, Shoenfeld Y, Bakimer R, et al. In vitro T-cell functions specific to an anti-DNA idiotype and serological markers in patients with systemic lupus erythematosus. J Clin Immunol 1988;8:178-187
51. Luger D, Dayan M, Zinger H, et al. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004;24:579-590 (Pubitemid 40933109)
52. + cells and TGF-β. Proc Natl Acad Sci USA 2006;103:8810-8815
53. Sharabi A, Mozes E. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. J Immunol 2008;181:3243-3251
54. Sharabi A, Luger D, Ben-David H, et al. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol 2007;179:4979-4987
55. Sela U, Dayan M, Hershkoviz R, et al. The negative regulators Foxj1 and Foxo3a are upregulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur J Immunol 2006;36:2971-2980 (Pubitemid 44782571)
56. Sela U, Dayan M, Hershkoviz R, et al. A peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3. J Immunol 2008;180:1584-1591
57. Available from: www.tevapharm.com